Eva
Lumbreras González
Investigadora desde 2014
Publicaciones (28) Publicaciones de Eva Lumbreras González
2024
2022
-
25-Hydroxyvitamin D Serum Levels Linked to Single Nucleotide Polymorphisms (SNPs) (rs2228570, rs2282679, rs10741657) in Skeletal Muscle Aging in Institutionalized Elderly Men Not Supplemented with Vitamin D
International Journal of Molecular Sciences, Vol. 23, Núm. 19
-
ALL-268 Genetic Classification of B-Cell Precursor Adult Acute Lymphoblastic Leukemia Patients Enrolled in LAL19 Trial from the Pethema Group: Response to Treatment and Survival
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S199
2021
-
Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients
Annals of Hematology, Vol. 100, Núm. 8, pp. 1995-2004
-
Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia
Haematologica, Vol. 106, Núm. 8, pp. 2215-2223
2020
-
Comprehensive custom ngs panel validation for the improvement of the stratification of b-acute lymphoblastic leukemia patients
Journal of Personalized Medicine, Vol. 10, Núm. 3, pp. 1-21
-
Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients
Pharmacogenomics Journal, Vol. 20, Núm. 5, pp. 664-671
-
Machine learning applied to gene expression analysis of T-lymphocytes in patients with cGVHD
Bone Marrow Transplantation
2019
-
Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation
Annals of Hematology, Vol. 98, Núm. 9, pp. 2151-2162
-
Redefining synchronous colorectal cancers based on tumor clonality
International Journal of Cancer, Vol. 144, Núm. 7, pp. 1596-1608
2018
-
Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia
Leukemia and Lymphoma, Vol. 59, Núm. 5, pp. 1095-1104
-
Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia
British Journal of Haematology, Vol. 182, Núm. 3, pp. 373-383
2016
-
MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion
Leukemia Research, Vol. 46, pp. 30-36
-
Pharmacogenetics and pharmacogenomics as tools in cancer therapy
Drug Metabolism and Personalized Therapy, Vol. 31, Núm. 1, pp. 25-34
-
The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab
British journal of haematology, Vol. 172, Núm. 3, pp. 428-438
2015
-
Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations
British Journal of Haematology
-
Fluorescence in situ hybridization analysis does not increase detection rate for trisomy 8 in chronic myelomonocytic leukemia
Leukemia and Lymphoma
2013
-
Alteration in Endoglin-Related Angiogenesis in Refractory Cytopenia with Multilineage Dysplasia
PLoS ONE, Vol. 8, Núm. 1
-
Response to lenalidomide in myelodysplastic syndromes with del(5q): Influence of cytogenetics and mutations
British Journal of Haematology, Vol. 162, Núm. 1, pp. 74-86
-
Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing
Genes Chromosomes and Cancer, Vol. 52, Núm. 12, pp. 1167-1177